Rapport Therapeutics (RAPP) Current Leases (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Current Leases data on file, last reported at $2.6 million in Q1 2026.

• Current Leases for Q1 2026 came in at $2.6 million, up 159.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (up 159.42% YoY), and the FY2025 annual result was $2.8 million, up 273.81% from the prior year.
• Current Leases declined to $2.6 million in Q1 2026 per RAPP's latest filing, from $2.8 million in the prior quarter.
• Over five years, Current Leases peaked at $2.8 million in Q4 2025 and troughed at $670000.0 in Q4 2023.
• A 4-year average of $1.5 million and a median of $1.0 million in 2025 frame the typical range for Current Leases.
• The sharpest annual moves came in 2024 and 2025: Current Leases increased 10.0% in 2024, then soared 273.81% in 2025.
• A 4-year view of Current Leases shows it stood at $670000.0 in 2023, then advanced by 10.0% to $737000.0 in 2024, then soared by 273.81% to $2.8 million in 2025, then fell by 5.08% to $2.6 million in 2026.
• Business Quant data shows RAPP's Current Leases at $2.6 million in Q1 2026, $2.8 million in Q4 2025, and $2.5 million in Q3 2025.